Skip to main
RVMD

Revolution Medicines (RVMD) Stock Forecast & Price Target

Revolution Medicines (RVMD) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 42%
Buy 53%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Revolution Medicines is well-positioned to capitalize on the large and growing market for targeted therapies in the precision oncology space, with a robust pipeline of direct and companion inhibitors targeting RAS-addicted cancers. The company's recent positive data for its RAS(ON) inhibitors and promising clinical collaborations, coupled with its strong financial position, make it an attractive investment opportunity in the oncology therapeutics sector.

Bears say

Revolution Medicines is facing fierce competition in the field of RAS-targeted cancer therapies, with multiple other RAS G12C inhibitors in development by larger pharmaceutical companies. Additionally, while the initial data for their lead candidate shows promise, it is still early and the efficacy and safety profile compared to established treatments remains to be seen. This, combined with the company's relatively limited pipeline and partnership-based business model, make it a risky investment at this time.

Revolution Medicines (RVMD) has been analyzed by 19 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 53% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Revolution Medicines and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Revolution Medicines (RVMD) Forecast

Analysts have given Revolution Medicines (RVMD) a Buy based on their latest research and market trends.

According to 19 analysts, Revolution Medicines (RVMD) has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $192.63, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $192.63, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Revolution Medicines (RVMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.